Cargando…
Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms
Vigabatrin, the first therapeutic agent to be approved by the Food and Drug Administration for the treatment of infantile spasms, as well as for adjunctive use in the treatment of refractory complex partial epilepsy, represents an important advance for patients with difficult-to-manage epilepsy. Thi...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2987507/ https://www.ncbi.nlm.nih.gov/pubmed/21127692 http://dx.doi.org/10.2147/NDT.S5235 |